Abstract 594P
Background
MET alteration, as promising rare target, plays the key role in the development of NSCLC. However, the treatment pattern and efficacy for Chinese NSCLC patients (pts) with MET alteration in real-world setting is limited. Here, we report the treatment pattern and clinical outcome in Chinese NSCLC pts with MET alteration.
Methods
We performed a retrospective, multicenter study in NSCLC pts with MET alteration between Jul. 2021 and Sep. 2022 in China. Patient characteristics, gene profile, and treatment pattern were collected. The objective response rate (ORR) and time to treatment failure (TTF) were analyzed.
Results
202 NSCLC pts with MET alteration were collected. 117 MET exon 14 skipping mutation (MET ex14m) and MET amplification (amp) (MET NGS GCN≥3.5) pts with subsequent efficacy assessment and follow-up data were included for analysis. The ORR of pts with MET ex14m received 1L savolitinib (savo mono), other MET inhibitor (METi) and chemotherapy (chemo)-based regimen were 56.3%, 16.7%, 36.3%, respectively. The ORR of pts with de novo MET amp received savo, other METi, and chemo-based regimen as 1st-line therapy were 66.7%, 0, 20%, respectively. The ORR of post EGFR/ALK-TKI resistance pts with MET amp (resistant MET amp) received savo mono, savo plus osimertinib (osi), other METi and chemo-based regimen were 12.5%, 43.8%, 0, 14.2%, respectively. (Table) Median TTF of 1L savo mono in pts with MET ex14m was 12.6months and median TTF of savo plus osi in pts with resistant MET amp was 11.3 months. Savo discontinuation due to adverse events occurred in MET ex14m, de novo MET amp and resistant MET amp pts were 18.7%, 33.3%, and 7%, respectively. The safety profile of savo were similar to previously reported data. Table: 594P
The ORR result in the analysis
| MET ex14m (n=44) | De novo MET amp (n=16) | Resistant MET amp (n=57) | |||||
| n | ORR | n | ORR | n | ORR | ||
| 1L | Savo | 16 | 56.3% | 3 | 66% | NA | |
| Other METi | 6 | 16.7% | 3 | 0% | |||
| Chemo | 22 | 36.3% | 10 | 20% | |||
| 2L+ | Savo | 14 | 42.8% | 2 | 50% | 8 | 12.5% |
| Savo+osi | 2 | 50% | 2 | 50% | 32 | 43.8% | |
| Other METi | 3 | 0 | 0 | NA | 3 | 0 | |
| Chemo | 23 | 26.1% | 14 | 28.5% | 14 | 14.2% |
Conclusions
The real-world analysis results showed the promising clinical benefit of savo in NSCLC pts with MET alterations and the acceptable safety. Follow-up of these pts are still ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract